Abstract
Myeloid-derived suppressor cells (MDSCs) arise from myeloid progenitors in the bone marrow and, under the influence of tumor- and immune-cell-derived cytokines, chemokines, and growth factors, enhance immunosuppressive activity within the tumor microenvironment (TME). Noncoding RNAs (ncRNAs)—including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs)—have emerged as critical regulators of MDSC biology. Recent evidence has shown that ncRNAs are intimately involved in MDSC recruitment, differentiation, and suppressive function by modulating key signaling pathways, including STAT3, NF-κB, and PI3K/AKT. This review synthesizes current understanding of how ncRNAs regulate MDSCs and discusses implications for cancer progression and therapeutic development.
The Challenge of the Immunosuppressive Tumor Microenvironment
A primary obstacle in cancer therapy is the "immunosuppressive tumor microenvironment" (TME), a biological shield that enables cancer cells to evade immune detection. Myeloid-derived suppressor cells (MDSCs) are central to this process. These immature myeloid cells are diverted from their normal developmental path to instead suppress T-cell activity and promote pro-tumorigenic processes like angiogenesis.
As shown in Figure 5, under normal conditions, common myeloid progenitors (CMPs) differentiate into mature monocytes, macrophages, and dendritic cells. However, in the presence of chronic inflammation or the TME, this process is hijacked, leading to the accumulation of MDSCs, specifically monocytic (M-MDSCs) and polymorphonuclear (PMN-MDSCs) subtypes.
Noncoding RNAs: The Regulatory Software of MDSCs
Once considered "junk DNA," noncoding RNAs (ncRNAs) are now recognized as master regulators of cellular function. This review categorizes how three main types of ncRNAs—miRNAs, lncRNAs, and circRNAs—control MDSC behavior:
- MicroRNAs (miRNAs): Small RNAs that typically silence gene expression. For instance, miR-1246 can be delivered via tumor-derived exosomes to "remote control" MDSC differentiation.
- Long Noncoding RNAs (lncRNAs): Larger molecules that act as scaffolds or decoys. HOTAIR, for example, can physically alter DNA packaging (epigenetic rewiring) to lock MDSCs into a suppressive state.
- Circular RNAs (circRNAs): Stable, loop-shaped RNAs that often act as "sponges," soaking up miRNAs to prevent them from hitting their targets, thereby fine-tuning MDSC activity.
Mechanisms of MDSC-Mediated Immunosuppression
MDSCs employ a variety of strategies to protect the tumor, many of which are regulated by ncRNAs.
As illustrated in Figure 6, these mechanisms include:
- Nutritional Depletion: MDSCs upregulate enzymes like Arginase-1 (ARG1) and Nitric Oxide Synthase (NOS), which deplete L-arginine, effectively "starving" T-cells.
- T-Cell Suppression: Direct and indirect inhibition of T-cell proliferation and function.
- Treg Enhancement: Promoting the proliferation of regulatory T-cells (Tregs) to further dampen the immune response.
- Tumor Promotion: Facilitating angiogenesis, metastasis, and extracellular matrix (ECM) remodeling.
Signaling Pathways and Clinical Outlook
The regulatory effects of ncRNAs often converge on core biochemical "switches" such as STAT3, NF-κB, and PI3K/AKT. Understanding these axes allows for a "pathway-centric" approach to therapy.
However, several hurdles remain for clinical translation. RNA molecules are inherently unstable and difficult to deliver specifically to MDSCs without affecting healthy cells. Future research must focus on improving delivery specificity and overcoming the context-dependent nature of ncRNA function. By dismantling the MDSC-mediated shield through RNA-targeted therapies, we may significantly enhance the efficacy of existing immunotherapies.
Summary updated